Composition
The main active ingredient: omeprazole. 1 capsule contains omeprazole pellets (in terms of omeprazole) 20 mg.
Among the excipients: mannitol (E 421), hypromellose, methacrylate copolymer dispersion, sodium lauryl sulfate, sodium hydrogen phosphate anhydrous, diethyl phthalate, sucrose, titanium dioxide (E 171), povidone, calcium carbonate, talc, polysorbate-80, sodium hydroxide.
Release form
It is available in the form of capsules containing pellets. The drug is a hard gelatin capsule with a dark red opaque body and an opaque cap of dark gray or black color. The capsules contain spherical granules from white to white with a creamy pink tint.
Pharmacological properties
Omeprazole Darnitsa is an antiulcer drug with an antisecretory effect. It easily penetrates the parietal cells of the gastric mucosa, accumulates and is activated at an acidic pH value. The active metabolite - sulfenamide - inhibits the H+, K+-ATPase of the secretory membrane of the parietal cells (proton pump), stops the release of hydrogen ions into the gastric cavity and blocks the final stage of hydrochloric acid secretion. Depending on the dose, it reduces the level of basal and stimulated secretion, the total volume of gastric secretion and the release of pepsin. Effectively inhibits night and day production of hydrochloric acid.
It has a bactericidal effect on Helicobacter pylori (H. pylori). Eradication of H. pylori, when used simultaneously with antibiotics, relieves the symptoms of the disease, allows for good healing of the affected mucosa and stable long-term remission, and reduces the likelihood of internal bleeding from the digestive tract.
With reflux infection.
In reflux ulcerative esophagitis, normalization of acid exposure in the esophagus and maintenance of intragastric pH - 4.0 for 24 hours with a decrease in the destructive properties of gastric contents (inhibition of the transition of pepsinogen to pepsin) contributes to the reduction of symptoms and complete healing of esophageal damage (healing rate exceeds 90%). Highly effective in the treatment of severe and complicated forms of erosive and ulcerative esophagitis resistant to H2-blockers of histamine receptors. Long-term therapy with Omeprazole Darnitsa capsules prevents relapses of reflux esophagitis and reduces the likelihood of complications.
In elderly patients, a slight increase in bioavailability and a decrease in the rate of excretion are allowed.
Indication
The drug Omeprazole Darnitsa is recommended for the complex treatment of the following pathologies:
- benign stomach ulcer;
- duodenal ulcer;
- peptic ulcer disease associated with taking nonsteroidal anti-inflammatory drugs;
- eradication of Helicobacter pylori (used as part of combination therapy with antibacterial agents);
- gastroesophageal reflux disease;
- prevention of aspiration of acidic stomach contents;
- Zollinger-Ellison syndrome;
- alleviation of symptoms of acid-dependent dyspepsia.
Contraindication
The drug Omeprazole Darnitsa is contraindicated in the following situations:
- hypersensitivity to omeprazole;
- possible allergy to substituted benzimidazoles or other components of the drug.
Omeprazole, like any proton pump inhibitors, is not recommended for use with nelfinavir and atazanavir.
Application
For gastric and duodenal ulcers: the daily dose is 1 capsule. In most cases, the course of treatment for duodenal ulcers is 4 weeks, for gastric ulcers - up to 8 weeks. If necessary, the daily dosage can be increased to 2 capsules.
In the treatment of duodenal ulcers
In the treatment and prevention of duodenal and gastric ulcers, gastroduodenal erosion and dyspeptic symptoms associated with the use of nonsteroidal anti-inflammatory drugs: the average daily dose is 20 mg. The course of treatment lasts from 4 to 8 weeks.
The course of treatment lasts from 4 to 8 weeks.
To suppress the activity of Helicobacter pylori bacteria: Omeprazole Darnitsa is recommended in a daily dose of 40 mg (20 mg 2 times a day) as part of complex therapy.
Special instructions
In the presence of any alarming symptom (e.g. significant weight loss not due to diet; frequent vomiting; dysphagia; vomiting with blood or mucus) and in the case of diagnosed gastric ulcer, malignant disease should be excluded at the beginning of therapy. Taking the drug Omeprazole Darnitsa may mask its symptoms and delay the establishment of the correct diagnosis.
Taking Omeprazole Darnitsa may mask its symptoms and delay the correct diagnosis.
Treatment with Omeprazole Darnitsa slightly increases the risk of developing gastrointestinal infections such as Salmonella and Campylobacter.
Side effects
When using Omeprazole Darnitsa, the risk of side effects increases:
- blurred vision, impaired acuity;
- dizziness;
- bronchospasms;
- constipation, diarrhea, flatulence;
- nausea, vomiting;
- dry mouth;
- stomatitis;
- microscopic colitis;
- hepatitis, with or without jaundice;
- liver failure.
Overdose
Possible signs of an overdose of Omeprazole Darnitsa include:
- attacks of nausea, vomiting;
- dizziness;
- abdominal pain;
- diarrhea;
- headaches;
Apathy, depression and confusion have been reported in rare cases. The symptoms resolve after discontinuation of Omeprazole.
Symptoms resolve after discontinuation of Omeprazole Darnitsa therapy.
Interactions
Concomitant use of atazanavir with Omeprazole is not recommended.
Storage conditions
Store in original packaging at temperatures up to 25 °C.
You can buy the drug OMEPRAZOLE CAPS. 0.02 №10 Darnytsia in any way, easily placing an order on our website anc.ua. Choose simple payment and delivery options yourself. Pick up the capsules at the nearest pharmacy or use the services of couriers.
